Alan P. Lyss

4.5k total citations
66 papers, 2.7k citations indexed

About

Alan P. Lyss is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Alan P. Lyss has authored 66 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Alan P. Lyss's work include Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Lung Cancer Research Studies (12 papers). Alan P. Lyss is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Lung Cancer Research Studies (12 papers). Alan P. Lyss collaborates with scholars based in United States, Canada and South Korea. Alan P. Lyss's co-authors include Douglas B. Cines, Raphael J. DeHoratius, James E. Herndon, Joan H. Schiller, Mark R. Green, Shaker R. Dakhil, Coleman K. Obasaju, Panos Fidias, Joseph Treat and David Waterhouse and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.

In The Last Decade

Alan P. Lyss

66 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan P. Lyss United States 27 1.2k 879 374 327 323 66 2.7k
Oscar Bertetto Italy 26 1.2k 1.0× 639 0.7× 318 0.9× 207 0.6× 561 1.7× 105 2.3k
Adnan Ezzat Saudi Arabia 26 1.4k 1.1× 667 0.8× 399 1.1× 548 1.7× 371 1.1× 83 3.2k
Gianmauro Numico Italy 28 1.1k 0.9× 776 0.9× 569 1.5× 399 1.2× 531 1.6× 115 2.6k
John Kouvaris Greece 24 586 0.5× 646 0.7× 332 0.9× 238 0.7× 325 1.0× 111 2.1k
Jean‐François Morère France 31 2.5k 2.0× 1.3k 1.5× 666 1.8× 581 1.8× 498 1.5× 216 4.0k
James F. Bishop Australia 29 1.6k 1.3× 624 0.7× 537 1.4× 330 1.0× 407 1.3× 118 3.0k
Linda Duska United States 35 1.2k 1.0× 575 0.7× 679 1.8× 332 1.0× 845 2.6× 232 4.4k
Robert Sidlow United States 17 2.7k 2.2× 824 0.9× 473 1.3× 150 0.5× 257 0.8× 24 4.0k
Cinzia Orlandini Italy 29 2.2k 1.8× 877 1.0× 622 1.7× 630 1.9× 748 2.3× 74 3.7k
Franz M.N.H. Schramel Netherlands 25 1.3k 1.0× 2.3k 2.6× 266 0.7× 166 0.5× 449 1.4× 110 2.9k

Countries citing papers authored by Alan P. Lyss

Since Specialization
Citations

This map shows the geographic impact of Alan P. Lyss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan P. Lyss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan P. Lyss more than expected).

Fields of papers citing papers by Alan P. Lyss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan P. Lyss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan P. Lyss. The network helps show where Alan P. Lyss may publish in the future.

Co-authorship network of co-authors of Alan P. Lyss

This figure shows the co-authorship network connecting the top 25 collaborators of Alan P. Lyss. A scholar is included among the top collaborators of Alan P. Lyss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan P. Lyss. Alan P. Lyss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramalingam, Suresh S., Suzanne E. Dahlberg, Chandra P. Belani, et al.. (2019). ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.. Journal of Clinical Oncology. 37(15_suppl). 9002–9002. 2 indexed citations
2.
3.
4.
Kernstine, Kemp H., James Moon, Michael Kraut, et al.. (2014). Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220. The Annals of Thoracic Surgery. 98(2). 402–410. 27 indexed citations
5.
Dy, Grace K., Sumithra J. Mandrekar, Garth D. Nelson, et al.. (2012). A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528. Journal of Thoracic Oncology. 8(1). 79–88. 36 indexed citations
6.
Yao, Song, William E. Barlow, Kathy S. Albain, et al.. (2010). Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Research and Treatment. 124(2). 433–439. 23 indexed citations
7.
Northfelt, Donald W., Jake Allred, Timothy J. Hobday, et al.. (2008). Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1063–1063. 2 indexed citations
8.
9.
Bogart, Jeffrey A., James E. Herndon, Alan P. Lyss, et al.. (2004). 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. International Journal of Radiation Oncology*Biology*Physics. 59(2). 460–468. 116 indexed citations
10.
Akerley, Wallace, James E. Herndon, Merrill J. Egorin, et al.. (2003). Weekly, high‐dose paclitaxel in advanced lung carcinoma. Cancer. 97(10). 2480–2486. 54 indexed citations
11.
Payne, Richard, Paul Coluzzi, Lowell L. Hart, et al.. (2001). Long-Term Safety of Oral Transmucosal Fentanyl Citrate for Breakthrough Cancer Pain. Journal of Pain and Symptom Management. 22(1). 575–583. 76 indexed citations
12.
Vogelzang, N. J., James E. Herndon, Antonius A. Miller, et al.. (1999). High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Annals of Oncology. 10(5). 597–600. 32 indexed citations
13.
Lyss, Alan P., et al.. (1993). A phase II trial of gallium nitrate in advanced previously untreated colorectal cancer. Investigational New Drugs. 11(4). 335–336. 2 indexed citations
14.
Kornblith, Alice B., Donna Hollis, E Zuckerman, et al.. (1993). Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.. Journal of Clinical Oncology. 11(11). 2081–2089. 67 indexed citations
15.
Barrios, Carlos H., et al.. (1992). Evaluation of an Implantable Venous Access System in a General Oncology Population. Oncology. 49(6). 474–478. 57 indexed citations
16.
17.
Lyss, Alan P., et al.. (1992). Intensive Etoposide and Carboplatin Chemotherapy for Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 15(5). 399–404. 4 indexed citations
18.
McGuire, Andrea H., Farrokh Dehdashti, Barry A. Siegel, et al.. (1991). Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.. PubMed. 32(8). 1526–31. 192 indexed citations
19.
Lyss, Alan P., et al.. (1989). Vindesine and Mitomycin C in Metastatic Breast Cancer. Oncology. 46(6). 357–359. 4 indexed citations
20.
Lyss, Alan P.. (1987). Systemic treatment for prostate cancer. The American Journal of Medicine. 83(6). 1120–1128. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oscar Bertetto Breakdown of academic impact, for papers by Adnan Ezzat Breakdown of academic impact, for papers by Gianmauro Numico Breakdown of academic impact, for papers by John Kouvaris Breakdown of academic impact, for papers by Jean‐François Morère Breakdown of academic impact, for papers by James F. Bishop Breakdown of academic impact, for papers by Linda Duska Breakdown of academic impact, for papers by Robert Sidlow Breakdown of academic impact, for papers by Cinzia Orlandini Breakdown of academic impact, for papers by Franz M.N.H. Schramel
Rankless by CCL
2026